Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
about
Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.A new drug design targeting the adenosinergic system for Huntington's diseaseRescuing the Corticostriatal Synaptic Disconnection in the R6/2 Mouse Model of Huntington's Disease: Exercise, Adenosine Receptors and AmpakinesDopamine and glutamate in Huntington's disease: A balancing act.Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of diseaseHistory and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum.BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.Selective A2A receptor antagonist SCH 58261 modulates striatal oxidative stress and alleviates toxicity induced by 3-Nitropropionic acid in male Wistar rats.In Vivo PET Imaging of Adenosine 2A Receptors in Neuroinflammatory and Neurodegenerative Disease.Impact of Coffee and Cacao Purine Metabolites on Neuroplasticity and Neurodegenerative Disease.Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.The Role of Adenosine Tone and Adenosine Receptors in Huntington's DiseaseComplex behavioral and synaptic effects of dietary branched chain amino acids in a mouse model of amyotrophic lateral sclerosis
P2860
Q24657796-B78D7CED-2B8C-4C7D-A916-5362DF8D67DBQ27005950-B8919832-F353-4A90-B43E-E3E4A23447A1Q27335053-BAA31994-D4CC-487F-A21D-59F5F73A8BD0Q33705003-289C7E44-5EE3-4A19-97B2-6C3557E25A6AQ37734563-9722F07D-E249-4FF3-921E-42CE7A99B4EDQ37996350-7AA7AE85-B91B-4969-8B71-45C860B047C7Q38395423-6592BF57-5525-468A-88CF-972DFE593C8DQ39013000-B2D979BC-9FA6-407F-AD80-388738A376D0Q45291563-A47687D1-A71F-4B53-96BF-3609B0439410Q46323118-9C37026A-0839-4F5E-85F4-E7A7D8A0C88DQ47853027-B4C73B3E-1D5A-470B-A377-CF330CFBFF41Q50125651-064922C5-0D6E-437E-B74A-66CD1177B512Q55266660-0FD4211B-1FAD-4204-AA27-F67F6C1994D0Q57896358-CAEBA414-0019-4D25-8694-A8C5813C140BQ58291143-6CAC995C-17CF-4904-94C8-78D0D32B8584
P2860
Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@en
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@nl
type
label
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@en
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@nl
prefLabel
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@en
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@nl
P2093
P1476
Behavioral and electrophysiolo ...... 6/2 Huntington's disease mice.
@en
P2093
Calamandrei G
Domenici MR
Lastoria G
Potenza RL
Scattoni ML
P304
P356
10.1016/J.NBD.2007.07.009
P577
2007-07-24T00:00:00Z